Chief Legal Officer and Secretary · Kura Oncology, Inc. (KURA)

Teresa Bair

FY2024 is the first fiscal year CompBrief holds for Teresa Bair as a named executive officer of Kura Oncology; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$2,271,872

Salary $468,520Stock awards $710,400

4th of 4 named executive officers at Kura Oncology by FY2024 total.

4 named officers on file for Kura Oncology, FY2024

Teresa Bair’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 4 equity grants, each cited to its filing
  • KURA’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Kura Oncology’s whole pay program stands against its peers

  • Kura Oncology’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on KURA→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 11, 2025 (DEF 14A).

Free

Get Teresa Bair’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Teresa Bair compensation by year

Kura Oncology Summary Compensation Table · the one fiscal year held
In US dollars, as Kura Oncology reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024
Salary$468,520
Bonus$0
Stock awards$710,400
Option awards$816,451
Non-equity incentive$246,207
Pension and deferred compensation$0
All other$30,294
Total$2,271,872

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Kura Oncology, Inc. DEF 14A filed April 11, 2025, accession 0000950170-25-053335, and prior-year filings.

How this page was built: the Kura Oncology, Inc. filed document, accession 0000950170-25-053335. Every figure is read from that document and cited to the page and table it appears in. Filed April 11, 2025.

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
PSU146,700$1,277,757—
RSU46,250$402,838—
RSU17,344$151,066—
Option40,000—$17.51
Option75,157—$11.99
Option71,303—$15.36

Per the Outstanding Equity Awards at Fiscal Year-End table in Kura Oncology, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Kura Oncology’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Troy WilsonPresident and Chief Executive Officer$6,239,098
Stephen DaleFormer Chief Medical Officer$2,508,675
Kathleen FordChief Operating Officer$2,501,838
Teresa Bair · this pageChief Legal Officer and Secretary$2,271,872

The full Kura Oncology compensation record

free company brief

This page is one person within Kura Oncology's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Kura Oncology proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Kura Oncology's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Teresa Bair's compensation dossier · One-time report. No refunds.